Strategies for Assessment of Fluid Overload in Acute Decompensated Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-14

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart failure (HF) is the endstage of all heart disease, characterized by inability of either the left or right heart or both to maintain sufficient output of blood for the demands of the body at normal filling pressures. Patients with HF are often admitted to hospital with decompensation and treated with diuretics. Residual congestion at discharge is associated with increased risk of early rehospitalization and adverse outcomes. However, determination of residual decompensation is complicated and a large number of patients admitted with decompensated heart failure are likely discharged before optimal decongestion has been achieved. Lung ultrasound (LUS) is a promising method to determine residual decompensation with the evaluation of B-lines. In this study our primary aim is to evaluate if LUS together with echocardiographic evaluation of filling pressure according to the European Society of Cardiology (ESC) algorithm performs better than clinical assessment to determine fluid status and risk of early rehospitalization in patients hospitalized for AHF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction

NCT05479669

Heart Failure, Diastolic

RECRUITING

Fluid Restriction in Patients With Heart Failure

NCT04611594

Heart Failure, Systolic Heart Failure; With Decompensation Pulmonary Congestion

UNKNOWN NA

Evaluating Residual Congestion at Discharge in Acute Heart Failure Patients

NCT06993220

Acute Heart Failure (AHF) Congestive Heart Failure(CHF)

RECRUITING

POCUS-Guided Diuresis for Decompensated Heart Failure

NCT06921603

Heart Decompensation, Acute Acute Kidney Injuries

RECRUITING NA

Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation

NCT06555757

Heart Failure

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Decompensated Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Decompensated heart failure

Previously diagnosed heart failure presenting with decompensation to the emergency department

Lung ultrasound

Intervention Type OTHER

Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging

Echocardiography

Intervention Type OTHER

Comprehensive echocardiography with evaluation of filling pressures

Peripheral venous pressure

Intervention Type OTHER

Assessment of peripheral venous pressure

Magnetic resonance imaging

Intervention Type OTHER

Cardiac magnetic resonance imaging

Pulmonary scintigraphy

Intervention Type OTHER

Assessment of pulmonary perfusion with scintigraphy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung ultrasound

Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging

Intervention Type OTHER

Echocardiography

Comprehensive echocardiography with evaluation of filling pressures

Intervention Type OTHER

Peripheral venous pressure

Assessment of peripheral venous pressure

Intervention Type OTHER

Magnetic resonance imaging

Cardiac magnetic resonance imaging

Intervention Type OTHER

Pulmonary scintigraphy

Assessment of pulmonary perfusion with scintigraphy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Hospitalization for decompensated heart failure is defined as an event that meets all of the following criteria:

1. The patient is admitted to the hospital with a primary diagnosis of HF (previous echo mandatory)
2. The patient's length-of-stay in hospital extends for at least 24 hours
3. The patient exhibits documented new or worsening symptoms due to HF on presentation, including at least ONE of the following:

* Dyspnea (dyspnea with exertion, dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea)
* Decreased exercise tolerance
* Fatigue
* Other symptoms of worsened end-organ perfusion or volume overload (as determined by the medical judgement of the investigator)
4. The patient has objective evidence of new or worsening HF, consisting of at least two physical examination findings OR one physical examination finding and at least ONE laboratory criterion, including:

1. Physical examination findings considered to be due to heart failure, including new or worsened:

* Peripheral edema
* Increasing abdominal distention or ascites (in the absence of primary hepatic disease)
* Pulmonary rales/crackles/crepitations
* Increased jugular venous pressure and/or hepatojugular reflux
* S3 gallop
* Clinically significant or rapid weight gain thought to be related to fluid retention
2. Laboratory evidence of new or worsening HF, if obtained within 24 hours of presentation, including:

* Increased B-type natriuretic peptide (BNP)/ N-terminal pro-BNP (NT-proBNP) concentrations consistent with decompensation of heart failure (such as BNP \> 500 pg/mL or NT-proBNP \> 2,000 pg/mL). In patients with chronically elevated natriuretic peptides, a significant increase should be noted above baseline.
* Radiological evidence of pulmonary congestion
* Non-invasive diagnostic evidence of clinically significant elevated left- or right-sided ventricular filling pressure or low cardiac output. For example, echocardiographic criteria could include: E/e' \> 15 or D-dominant pulmonary venous inflow pattern.
* Invasive diagnostic evidence with right heart catheterization showing a pulmonary capillary wedge pressure (pulmonary artery occlusion pressure) ≥ 18 mmHg, central venous pressure ≥ 12 mmHg, or a cardiac index \< 2.2 L/min/m2
5. The patient receives initiation or intensification of treatment specifically for HF, including at least one of the following:

* Augmentation in oral diuretic therapy
* Intravenous diuretic or vasoactive agent (e.g., inotrope, vasopressor, or vasodilator)
* Mechanical or surgical intervention, including:

* Mechanical circulatory support (e.g. intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation, total artificial heart)
* Mechanical fluid removal (e.g., ultrafiltration, hemofiltration, dialysis)